[go: up one dir, main page]

PL1778209T3 - Sposoby i kompozycje do doustnego dostarczania FTS - Google Patents

Sposoby i kompozycje do doustnego dostarczania FTS

Info

Publication number
PL1778209T3
PL1778209T3 PL05787786T PL05787786T PL1778209T3 PL 1778209 T3 PL1778209 T3 PL 1778209T3 PL 05787786 T PL05787786 T PL 05787786T PL 05787786 T PL05787786 T PL 05787786T PL 1778209 T3 PL1778209 T3 PL 1778209T3
Authority
PL
Poland
Prior art keywords
fts
compositions
methods
oral delivery
treatment
Prior art date
Application number
PL05787786T
Other languages
English (en)
Inventor
Victor J Bauer
Original Assignee
Kadmon Corp Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kadmon Corp Llc filed Critical Kadmon Corp Llc
Publication of PL1778209T3 publication Critical patent/PL1778209T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C321/00—Thiols, sulfides, hydropolysulfides or polysulfides
    • C07C321/24—Thiols, sulfides, hydropolysulfides, or polysulfides having thio groups bound to carbon atoms of six-membered aromatic rings
    • C07C321/28—Sulfides, hydropolysulfides, or polysulfides having thio groups bound to carbon atoms of six-membered aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL05787786T 2004-08-18 2005-08-18 Sposoby i kompozycje do doustnego dostarczania FTS PL1778209T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US60236104P 2004-08-18 2004-08-18
EP05787786A EP1778209B8 (en) 2004-08-18 2005-08-18 Methods and compositions for oral delivery of fts
PCT/US2005/029389 WO2006023639A1 (en) 2004-08-18 2005-08-18 Methods and compositions for oral delivery of fts

Publications (1)

Publication Number Publication Date
PL1778209T3 true PL1778209T3 (pl) 2010-10-29

Family

ID=35447506

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05787786T PL1778209T3 (pl) 2004-08-18 2005-08-18 Sposoby i kompozycje do doustnego dostarczania FTS

Country Status (9)

Country Link
US (4) US8088756B2 (pl)
EP (3) EP1778209B8 (pl)
AT (2) ATE535237T1 (pl)
CA (1) CA2577310C (pl)
DE (1) DE602005021115D1 (pl)
ES (2) ES2343737T3 (pl)
MX (1) MX2007001929A (pl)
PL (1) PL1778209T3 (pl)
WO (1) WO2006023639A1 (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1778209B8 (en) * 2004-08-18 2010-06-16 Concordia Pharmaceuticals, Inc. Methods and compositions for oral delivery of fts
ATE485037T1 (de) * 2005-11-28 2010-11-15 Univ Ramot Krebsbehandlung mittels fts und 2-deoxyglucose
US8268889B2 (en) 2006-02-10 2012-09-18 Ramot At Tel-Aviv University Ltd. Treatment of ovarian cancer
WO2007144889A2 (en) * 2006-06-14 2007-12-21 Ramot At Tel Aviv University Ltd. Treatment of neurofibromatosis
EP2094260B1 (en) * 2006-12-19 2012-02-01 Ramot at Tel-Aviv University Ltd. Treatment of lung cancer
WO2011056542A1 (en) * 2009-10-26 2011-05-12 Ramot At Tel-Aviv University Ltd. Cancer therapy with combinations of fts with hdac inhibitors
JP6165744B2 (ja) * 2011-10-07 2017-07-19 パイシーズ セラピューティックス エルエルシーＰｉｓｃｅｓ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｌｃ Ｒａｓアンタゴニストによる悪性および非悪性疾患の治療
US9738614B2 (en) 2011-10-07 2017-08-22 Pisces Therapeutics, Llc Malignant and non-malignant disease treatment with Ras antagonists
KR20240041917A (ko) * 2021-07-27 2024-04-01 도레이 카부시키가이샤 암의 치료 및/또는 예방을 위한 의약품

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
IL107587A (en) * 1993-11-12 1998-08-16 Univ Ramot Farnesyl geranyl or geranyl-geranyl derivatives pharmaceutical compositions containing them and methods for their preparation
AU2859499A (en) * 1998-03-27 1999-10-18 Chong Kun Dang Corporation (streptomyces) sp. producing tautomycetin and immunosuppressant comprising tautomycetin as active ingredient
US20020115696A1 (en) * 1999-06-18 2002-08-22 Yoel Kloog Treatment of post-angioplasty restenosis and atherosclerosis with ras antagonists
US6462086B1 (en) 1999-06-18 2002-10-08 Ramot University Authority For Applied Research And Industrial Development Ltd. Non-malignant disease treatment with Ras antagonists
WO2002029031A2 (en) * 2000-10-04 2002-04-11 Ramot University Authority For Applied Research & Industrial Development Ltd. Isoprenoid-dependent ras anchorage (idra) proteins
US20020169183A1 (en) * 2001-03-08 2002-11-14 Villar Hugo O. Acridines as stimulators for Fas-mediated apoptosis
EP1390472A4 (en) * 2001-05-29 2004-11-17 Sirna Therapeutics Inc NUCLEIC ACID TREATMENT OF DISEASES OR SIDES RELATED TO RAS, HER2 AND HIV LEVELS
WO2004083458A1 (en) * 2003-03-20 2004-09-30 Universite Catholique De Louvain Medical use of ras antagonists for the treatment of capillary malformation
US20070054886A1 (en) * 2003-05-23 2007-03-08 Ramot At Tel Aviv University, Ltd. Ras antagonists for treating neurodegenerative disorders
AU2004266721A1 (en) * 2003-08-22 2005-03-03 University Of Virginia Patent Foundation Blockade of mTOR to prevent a hormonal adaptive response
EP1778209B8 (en) 2004-08-18 2010-06-16 Concordia Pharmaceuticals, Inc. Methods and compositions for oral delivery of fts
ATE485037T1 (de) 2005-11-28 2010-11-15 Univ Ramot Krebsbehandlung mittels fts und 2-deoxyglucose

Also Published As

Publication number Publication date
EP2301528B1 (en) 2013-04-03
ATE535237T1 (de) 2011-12-15
US20160271089A1 (en) 2016-09-22
EP2218451A1 (en) 2010-08-18
EP2218451B1 (en) 2011-11-30
US8088756B2 (en) 2012-01-03
CA2577310C (en) 2011-01-11
WO2006023639A1 (en) 2006-03-02
MX2007001929A (es) 2007-04-17
ATE466574T1 (de) 2010-05-15
ES2343737T3 (es) 2010-08-09
US20150191426A1 (en) 2015-07-09
EP1778209A1 (en) 2007-05-02
EP1778209B1 (en) 2010-05-05
CA2577310A1 (en) 2006-03-02
US20090226512A1 (en) 2009-09-10
EP1778209B8 (en) 2010-06-16
EP2301528A1 (en) 2011-03-30
ES2414861T3 (es) 2013-07-23
DE602005021115D1 (de) 2010-06-17
US20120082722A1 (en) 2012-04-05

Similar Documents

Publication Publication Date Title
EP4327888A3 (en) Oral formulations of cytidine analogs and methods of use thereof
FI3504187T3 (fi) Pridopidiinin käyttö toiminnallisen heikkenemisen hoitoa varten
WO2008040534A3 (en) Non-mucoadhesive film dosage forms
ES2916649T1 (es) Composiciones y usos para el tratamiento de la esclerosis múltiple
WO2008022189A3 (en) Administration of high potency platinum compound formulations by inhalation
NZ597378A (en) Treatment of multiple sclerosis with laquinimod
WO2009033717A3 (en) Use of gonadorelin as a therapeutic agent
MX2009002314A (es) Composiciones farmaceuticas que comprenden hgh para suministro oral.
PL1819227T3 (pl) Preparat farmaceutyczny decytabiny
WO2009033767A3 (en) Use of a peptide as a therapeutic agent
WO2009043454A3 (en) Use of pacap-27 as a therapeutic agent
UA105644C2 (uk) Способи лікування легеневих порушень складами ліпосомального амікацину
UA110463C2 (ru) ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ 4-{[9-ХЛОР-7-(2-ФТОР-6-МЕТОКСИФЕНІЛ)-5Н-ПІРИМІДО[5,4-d][2]БЕНЗАЗЕПІН-2-ІЛ]АМІНО}-2-МЕТОКСИБЕНЗОЙНОЇ КИСЛОТИ ДЛЯ ЛІКУВАННЯ РАКУ Й ІНШИХ ЗАХВОРЮВАНЬ І ПОРУШЕНЬ СТАНУ ЗДОРОВ'Я
IL196425A0 (en) Pharmaceutical compositions containing ibuprofen and famotidine
WO2007012019A3 (en) Medicaments containing famotidine and ibuprofen and administration of same
NZ595376A (en) Dental anesthetic comprising tetracaine and a vasoconstrictor for intranasal administration
AR062659A1 (es) Composicion de liberacion sostenida de levodopa y metodo para su uso
HRP20161197T1 (hr) 24-norudca za liječenje autoimunog hepatitisa
NZ591525A (en) Methods of treatment of complicated skin and skin structure infections using single doses of oritavancin
WO2006138608A3 (en) Pharmaceutical compositions and use thereof
NO20080244L (no) Doseringsstyring for prasugrel
MY148125A (en) Compounds
WO2009040085A3 (en) Use of exendin-4 and optionally salusin-alpha as therapeutic agent(s)
NO20082672L (no) Anvendelse av cikletanin og andre fluorpyridiner for behandling av systolisk-dominant hypertensjon, isolert hypertensjon, oket pulstrykk og generell hypertensjon
PL1778209T3 (pl) Sposoby i kompozycje do doustnego dostarczania FTS